** Drug developer Checkpoint Therapeutics' CKPT.O shares rise 66% to $4.10 premarket
** India's Sun Pharmaceutical Industries SUN.NS will buy Checkpoint Therapeutics for $355 million, the companies said on Sunday
** Upfront cash payment of $4.10 per share, at a 66% premium to stock's last close
** CKPT's controlling arm Fortress Biotech FBIO.O would receive royalty payments based on future sales of co's skin cancer drug Unloxcyt during a specified term
** FBIO shares rise 12.3% to $1.73 before the bell
** The deal expected to be completed in Q2 2025
** CKPT has risen 13.8% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.